Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001057746 | SCV001222255 | pathogenic | not provided | 2024-12-10 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 3020 of the EYS protein (p.Ile3020Thr). This variant is present in population databases (no rsID available, gnomAD 0.004%). This missense change has been observed in individuals with retinitis pigmentosa (PMID: 26787102, 31213501, 36819107; internal data). ClinVar contains an entry for this variant (Variation ID: 853016). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt EYS protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. |
Mendelics | RCV002249665 | SCV002519625 | pathogenic | Retinitis pigmentosa 25 | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV002249665 | SCV004192954 | likely pathogenic | Retinitis pigmentosa 25 | 2023-12-30 | criteria provided, single submitter | clinical testing | |
Dept Of Ophthalmology, |
RCV003890204 | SCV004707381 | uncertain significance | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Institute of Human Genetics, |
RCV003890204 | SCV005070544 | likely pathogenic | Retinal dystrophy | 2020-01-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002249665 | SCV005673231 | likely pathogenic | Retinitis pigmentosa 25 | 2024-02-13 | criteria provided, single submitter | clinical testing |